Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Mint - Oct 29, 2026

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

Read full article

More News

About Us
Logo

In-Depth Science delivers comprehensive and compelling news and analysis on everything science and technology, seven days a week in a reader-friendly format.

Contact us: sales[at]indepthscience.com

Copyright © 2015 - 2026 In-Depth Science. All Rights Reserved.